SCHEMBL6169214

SCHEMBL6169214

Cc1noc(-c2ccc(S(N)(=O)=O)cc2)c1-c1ccc(F)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 16/20 0.64
PTGS1 P23219 8/20 0.56
CA1 P00915 4/20 0.54
CA2 P00918 4/20 0.54
CA4 P22748 3/20 0.54
CA7 P43166 2/20 0.54
MAOA P21397 1/20 0.51
MAOB P27338 1/20 0.51
CA9 Q16790 3/20 0.48
CA12 O43570 2/20 0.48
CA5A P35218 2/20 0.48
CA5B Q9Y2D0 2/20 0.48
MT-CO2 P00403 1/20 0.48
LMNA P02545 1/20 0.48
CA3 P07451 1/20 0.48
ADRB2 P07550 1/20 0.48
ADRB1 P08588 1/20 0.48
CYP3A4 P08684 1/20 0.48
ADORA3 P0DMS8 1/20 0.48
CHRM1 P11229 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6169079 1.00 PTGS2 (0.64) PTGS2PTGS1CA1CA2CA4
SCHEMBL6168306 0.89 CA2 (0.56) PTGS2PTGS1CA1CA2CA4
SCHEMBL6169868 0.89 CA2 (0.56) PTGS2PTGS1CA1CA2CA4
SCHEMBL6013960 0.87 PTGS2 (0.63) PTGS2PTGS1CA1CA2CA4
SCHEMBL5698533 0.87 PTGS2 (0.63) PTGS2PTGS1
SCHEMBL6169136 0.87 PTGS2 (0.63) PTGS2PTGS1CA1CA2CA4
SCHEMBL6517910 0.86 CA2 (0.54) PTGS2PTGS1CA1CA2CA4
SCHEMBL6170551 0.86 CA1 (0.54) PTGS2PTGS1CA1CA2CA4
SCHEMBL6170394 0.86 CA1 (0.54) PTGS2PTGS1CA1CA2CA4
SCHEMBL6170854 0.85 KIF11 (0.57) PTGS2PTGS1CA1CA2CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1528059-A2 Substituted isoxazoles for the treatment of inflammation G.D. Searle LLC (US) 2005-05-04 EP claimed
CN-1442139-A Medicinal composition for treating inflammation SEARLE & CO (US) 2003-09-17 CN claimed
CN-1107058-C Substituted isoxazoles for the treatment of disorders SEARLE & CO (US) 2003-04-30 CN claimed
EP-1223167-A2 Substituted isoxazoles for the treatment of inflammation G.D. Searle & Co. (US) 2002-07-17 EP claimed
EP-0809636-A1 SUBSTITUTED ISOXAZOLES FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1997-12-03 EP claimed
WO-1996025405-A1 SUBSTITUTED ISOXAZOLES FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1996-08-22 WO claimed
CN-1214790-C Medicinal composition for treating inflammation SEARLE & CO (US) 2005-08-17 CN disclosed
EP-1528059-A2 Substituted isoxazoles for the treatment of inflammation G.D. Searle LLC (US) 2005-05-04 EP disclosed
CN-1442139-A Medicinal composition for treating inflammation SEARLE & CO (US) 2003-09-17 CN disclosed
CN-1107058-C Substituted isoxazoles for the treatment of disorders SEARLE & CO (US) 2003-04-30 CN disclosed
EP-1223167-A2 Substituted isoxazoles for the treatment of inflammation G.D. Searle & Co. (US) 2002-07-17 EP disclosed
CN-1181075-A Substituted isoxazoles for the treatment of disorders SEARLE & CO (US) 1998-05-06 CN disclosed
EP-0809636-A1 SUBSTITUTED ISOXAZOLES FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1997-12-03 EP disclosed
WO-1996025405-A1 SUBSTITUTED ISOXAZOLES FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1996-08-22 WO disclosed